N&O Index Card Listings

Displaying 1-6 of 6 results.
Glaxo Inc.
  • Glaxo gets OK to sell new drug; Zofran stops nausea during chemotherapy - Ja 8 91 1D
  • Glaxo reassigns top executives - Ja 10 91 6C
  • Glaxo won't join Durham downtown project - Ja 15 91 5B
  • Glaxo plans to build $20 million facility in RTP - Ja 29 91 1D
  • Glaxo gives $1 million to NCCU for sciences - Fe 13 91 2B
  • Glaxo Inc. numbers revealing - Fe 24 91 1F
  • Glaxo taps Haber for senior post - Mr 12 91 1D
  • Glaxo denies reports it will cut retail prices - Mr 22 91 6C
  • Glaxo gives $1 million for Duke professorship - Ap 16 91 1D
  • Glaxo's darling targeted; Generic firm's suit challenges Zantac - My 12 91 1F
  • Glaxo shares take off - My 25 91 10C
  • Glaxo migraine drug (Imitrex) - My 26 91 1F
  • Glaxo Inc. child-care centers are planned; Construction slated to be finished in year - Jn 5 91 6C
  • Studies a shot in the arm for Glaxo migraine drug - Jn 9 91 2F
  • Glaxo stock falls after Barron's questions potential of big drugs - Jn 18 91 1D
  • Glaxo begins marketing new skin-disease drug - Jy 17 91 10C
  • Glaxo says ruling helps in patent squabble with SmithKline - Jy 30 91 1D
  • Glaxo opens new center for training sales force - Au 1 91 7C
  • Glaxo transfers building to UNC - Au 13 91 3B
  • RTP's Glaxo reports 17% surge in sales - Se 13 91 6C
  • Glaxo's ulcer drug could lead shift to over-the-counter sales - Se 15 91 3F
  • Glaxo retains right to develop Zantac for sale over counter - Oc 12 91 8C
  • Glaxo patent tested; Canadian firm eyes ulcer drug - Oc 22 91 1D
  • Glaxo gets go-ahead for migraine drug; Treatment expected to be a big seller - Oc 26 91 10C
  • Glaxo, Calif. firm team up on metabolism drug - Oc 30 91 9C
  • Glaxo eyes Kenly plant - No 3 91 1F
  • Ulcer patient claims Glaxo ties tainted judge - No 9 91 10C
  • Glaxo to buy plant Bristol-Myers closed (in Kenly) - No 13 91 9C
  • Glaxo completes deal for former Bristol plant - No 21 91 5C
  • Glaxo grants to help reduce infant deaths - No 22 91 5B
  • Former Glaxo worker (DONNELLY) admits selling samples; Sale of ulcer drug Zantac spanned 21
  • months - No 27 91 9C
  • Glaxo Inc. to reorganize roles of some executives - De 20 91 6C
  • 212
Glaxo Inc.
  • Glaxo to begin testing AIDS inhibitor drug - Oc 20 88 22A
  • Glaxo starts construction of new research facility - No 1 88 2D
  • Glaxo planning more No 6 88 1I
  • Glaxo planning $90 million plant in Durham No 17 88 3C
  • Durham to get boost from Glaxo project No 18 88 1
  • Glaxo promotes vice president (Steigrod) No 24 88 8B
  • Glaxo on the air (Public awareness) - De 4 88 1I
  • Glaxo signs agreement to develop AIDS drug - De 6 88 1D
  • Glaxo reorganizing in Latin America - De 16 88 6B
Glaxo Inc.
  • Glaxo expects half of sales from Zantac, board told - Ja 9 90 1D
  • Glaxo gives $250,000 for art exhibit - Ja 18 90 1B
  • Glaxo decides against Durham plant; Firm still plans downtown office building for up to 300 workers - Ja 23 90 1B
  • Glaxo executive (Sanders) named director of parent firm - Fe 1 90 5C
  • Glaxo develops guide for pharmacy students - Fe 13 90 1D
  • Durham school may be bought by Glaxo - Fe 24 90 1B
  • Carpeting Glaxo floor huge job for Eatmans - Mr 9 90 7c
  • Ulcer drug boosts Glaxo profits - Mr 16 90 7C
  • Glaxo adds executive vice president (Ingram) - Mr 17 90 8C
  • President honors Glaxo volunteers - Mr 23 90 2B
  • Sanford, Helms win tax break for Glaxo - Ap 25 90 1
  • Glaxo finds profits in stepped-up effort to lobby Congress - Ap 26 90 1B
  • Glaxo to update analysts - My 6 90 1F
  • Council agrees to sell school land to Glaxo - Jn 1 90 2B
  • Glaxo Holdings close to getting approval for drugs - Jn 1 90 7C
  • Glaxo unit president elected to firm's board - Jn 14 90 7C
  • Glaxo examines new drug for ulcers - Jn 17 90 4F
  • Glaxo to seek approval for migraine treatment - Jn 26 90 1D
  • Glaxo Inc. begins work on new training center - Jn 28 90 6C
  • Glaxo formally asks FDA to approve drug (sumatriptan for migraine) - Jy 3 90 1D
  • Way clear for Glaxo to buy Durham school - Jy 11 90 2B
  • Glaxo agrees to cut drug prices for state Medicaid programs - Jy 25 90 5B
  • Glaxo, Gilead plan may yield new cancer drugs - Jy 27 90 5C
  • Shaw boosts its efforts in sciences - Jy 27 90 5B
  • Glaxo parent plans $800 million complex - Au 10 90 5C
  • Glaxo buys license from RTI, sells drug - Au 30 90 9C
  • Glaxo's 'Sir Paul' center - Se 2 90 1F
  • Ulcer drug lifts profits for Glaxo - Se 21 90 7C
  • British executive (Sykes) to direct Glaxo RTP center - Oc 4 90 6C
  • Glaxo to shift RTP focus from heart research - Oc 11 90 6C
  • Glaxo Inc. - A chronology - Oc 14 90 12A
  • RTP baby Glaxo grows up; Drug firm crowns decade of growth with new center - Oc 14 90 1
  • Amid changes, Glaxo unveils research center - Oc 19 90 6C
  • The urban image: A $450 million experiment in productivity; Glaxo's campus hopes to get results from good design - No 4 90 1H
  • Glaxo is teller's pet - No 18 90 1F
  • Glaxo, FBI foil attempt to sell firm rival's secrets - No 23 90 7C
  • Delayed Glaxo decision worries backers of Durham's downtown - No 24 90 1B
  • Rival drug giants face secrets deal anew - No 24 90 1B
  • Glaxo Canada to help develop, sell cancer and virus treatments - No 29 90 6C
  • Glaxo presentation impresses analysts - De 5 90 6C
  • Glaxo seeks OK for migraine tablet - De 18 90 1D
Glaxo Inc.
  • Glaxo expands (Photo) - Ja 10 89 1D
  • New ulcer drug could slow Glaxo's Zantac sales growth slightly - Ja 14 89 8B
  • Glaxo gives $80,000 to 37 arts agencies - Ja 28 89 2C
  • Burroughs Wellcome has direction; Glaxo still narrowing choices - Ja 29 89 3J
  • Idaho company agrees to head Glaxo project - Fe 10 89 5B
  • Offices on same floor - Fe 26 89 1I
  • Glaxo names president of Latin American operations - Mr 2 89 10B
  • Glaxo endows Wake artists program - Mr 23 89 10T
  • Helms in Tasmania as Glaxo seeks edge in 'opium war' - Mr 25 89 1C
  • Glaxo effort aimed at new drugs - Ap 26 89 5B
  • Editorial: Checking a gift horse - Ap 29 89 16A
  • Glaxo says progress made in developing new drugs - My 6 89 8B
  • Mario promoted at Glaxo Holdings - My 10 89 5B
  • Glaxo chief says new chairman will come from outside firm - My 24 89 6B
  • Glaxo chief (Mario) says new drugs will build the future of firm - My 28 89 1I
  • Glaxo reports $1.5 billion in sales, hiring increase - Jn 2 89 6B
  • Glaxo gives grant for AIDS education program - Jn 9 89 8B
  • Glaxo may form venture capital fund to aid in product development - Jn 14 89 5B
  • Glaxo might be interested in Robins plant - Jn 17 89 5B
  • Glaxo to announce plant construction - Jn 17 89 5B
  • Glaxo expected to name chief executive officer - Jn 21 89 6B
  • New Glaxo chief (Sanders) ready for business - Jn 22 89 6B
  • Glaxo planning first public image campaign - Jy 6 89 7B
  • (Zebulon) Recreation program gets grant - Jy 6 89 2T
  • Glaxo research executive (Cuatrecasas) to leave drug company - Jy 11 89 1D
  • Theater receives grant from Glaxo - Au 10 89 4T
  • Glaxo pledges $75,000 for Duke minorities - Au 16 89 10A
  • Glaxo Inc. - a chronology - Se 10 89 17A
  • In narrowing its focus, Glaxo loses its star scientist - Se 10 89 1
  • Glaxo a step ahead on moving research site - Se 17 89 1I
  • Sale of ulcer drug helps increase net income of Glaxo by about 20% - Se 20 89 5B
  • Glaxo seeks follow-up for profitable anti-ulcer drug - Oc 15 89 1I
  • Glaxo gives contribution to series - No 2 89 9T
  • Glaxo looks outside for new prescription drugs - No 3 89 8B
  • Glaxo presents first profit-sharing awards - No 17 89 7B
  • Glaxo plans incinerator for complex - No 18 89 2C
  • Glaxo begins program to help asthma victims - No 29 89 12A
  • Glaxo ends development of potentially risky ulcer drug - De 5 89 1D
  • Glaxo tests lab in a lab - De 10 89 1G
  • Glaxo signs agreement on cystic fibrosis drug - De 14 89 5C
  • No-nonsense boss at Glaxo is leery of top-heavy firms - De 24 89 1G
Glaxo Inc.
  • RTP company may buy (old Zebulon Elementary) school - Jn 22 85 1C
  • Glaxo receives FDA approval to sell new antibiotic (Fortaz) - Jy 20 85 8B
  • Glaxo looking beyond Zantac - Au 27 85 1D
  • Glaxo plans to add research unit at RTP - Se 19 85 7B
  • Zantac boosts Glaxo's sales to healthy 78% gain - No 1 85 5C
  • Glaxo sues to block generic version of drug (Ceftazidime) No 16 85 12B
  • Glaxo loses ruling on generic drug No 21 85 7B
Glaxo Inc.
  • Glaxo will build large RTP center - Ja 1 88 1
  • Glaxo to market (heart) drugs for Hoffmann-LaRoche - Ja 8 88 5B
  • Casual drug firm president well-grounded in industry - Ja 19 88 2D
  • Glaxo on industry's fast track; Analysts unconvinced; 'one-product company' relies on Zantac - Ja 19 88 1D
  • Glaxo to change design of its drug packaging - Mr 2 88 5B
  • Company policies vary on minority employment - Mr 29 88 4D
  • Glaxo donates to Poland - Ap 3 88 1I
  • Glaxo moves to broaden sales base - Ap 6 88 6B
  • Glaxo forms units to sell various drugs - Ma 24 88 5D
  • Glaxo gives $150,000 for Tammy Lynn Center - Ma 24 88 2C
  • Glaxo executive glad to be back in Triangle - Jn 8 88 5B
  • Glaxo tops sales record in only 10 months - Jn 9 88 7B
  • Glaxo executive (Mario) promoted to top post - Jn 14 88 1D
  • Glaxo giving $250,000 toward center at Duke (for executive education programs) - Au 13 88 8B
  • Glaxo research unit to move - Au 17 88 7B
  • Glaxo Inc. gives Duke $1 million for heart center - Se 21 88 2C
  • Glaxo to give $1 million for endowment at Duke - Se 21 88 7B
  • Glaxo chairman (Mario) moving from Triangle to London - Oc 18 88 1D